Latest News for: kras

Edit

Extension for Upload of Client Records to KRAs for Validations (MCX - Multi Commodity Exchange of India Ltd)

Public Technologies 25 Dec 2025
Extension for Upload of Client Records to KRAs for Validations ... Non-upload of KYCs to KRAs is a non- compliance with the aforementioned regulatory requirements ... The KRA status of the said PANs shall be verified with the respective KRAs.
Edit

Extension for Upload of Client Records to KRAs for Validations (BSE Ltd)

Public Technologies 24 Dec 2025
Subject Extension for Upload of Client Records to KRAs for Validations ... Extension for Upload of Client Records to KRAs for Validations<_o3a_p> ... The KRA status of the said PANs shall be verified with the respective KRAs.
Edit

Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73

The Galveston Daily News 21 Dec 2025
... AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73.
Edit

Trethera Receives $2.7 Million NIH Grant, Validating the Potential of First-in-Class TRE-515 to Overcome KRAS ...

Nasdaq Globe Newswire 16 Dec 2025
$2.7M NIH grant evaluates TRE-515 with KRAS inhibitors in lung cancer, boosting Trethera’s FDA Fast Track pipeline with a novel approach to resistance ... .
Edit

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer

Business Wire 16 Dec 2025
... cancer (“mCRC”), specifically in patients with KRAS-mutant, microsatellite-stable (“MSS”) disease.
Edit

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer (Form 6-K) (Oncolytics Biotech Inc)

Public Technologies 16 Dec 2025
) Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer. 33% ORR achieved in second-line KRAS-mutant MSS colorectal ...
Edit

KRAS Inhibitors Market to Witness Explosive Growth at a CAGR of 35% During the Forecast ...

Nasdaq Globe Newswire 12 Nov 2025
G12C is the most prevalent KRAS mutation in NSCLC, making it a key target of current therapies. Following the success of KRAS G12C inhibitors, attention is shifting to KRAS G12D as the next major target.
Edit

Global KRAS Inhibitors Market Set to Surge at 35% CAGR by 2034 Across the US, ...

GetNews 10 Nov 2025
"Global KRAS Inhibitors Market" ... KRAS (Kirsten Rat Sarcoma viral oncogene) is the most frequently mutated of the three RAS genes, followed by NRAS and HRAS ... Among the three RAS genes, KRAS, NRAS, and HRAS-KRAS is the most frequently mutated.
Edit

SITC 2025 Poster Presentation: Dual targeting of TGF-b and EGFR with ficerafusp alfa shows superior antitumor activity over cetuximab in KRAS/BRAF wild-type MSS colorectal cancer cell lines (Bicara Therapeutics Inc)

Public Technologies 08 Nov 2025
) Dual targeting of TGF-β and EGFR with ficerafusp alfa shows superior antitumor activity over cetuximab in KRAS/BRAF wild-type MSS colorectal cancer cell lines ... MSS tumors and 50% are KRAS WT ... KRAS.
Edit

What does it take to earn $1 trillion pay? Here are Tesla's KRAs for Elon Musk

India Today 07 Nov 2025
What does it take to earn trillion pay Here are Teslas KRAs for Elon Musk ... .
Edit

AMPLIFY-7P Phase 2: T cell responses induced by lymph node-targeted amphiphile therapeutic cancer vaccine in patients with KRAS mutated pancreatic ductal adenocarcinoma (Elicio Therapeutics Inc)

Public Technologies 07 Nov 2025
in patients with KRAS mutated pancreatic ductal adenocarcinoma ... KRAS mutant ... 2 Mutant KRAS is a Promising Tumor Antigen. 1 Mutant KRAS Drives 25% of Solid Human Cancers ... Why Target mutated KRAS with Therapeutic Immunotherapy?.
Edit

KRAS Inhibitors Market on Track for Major Expansion by 2034, According to DelveInsight | Pfizer, ...

GetNews 28 Oct 2025
To Know in detail about the KRAS Inhibitors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here;. Some of the key facts of the KRAS Inhibitors Market Report. ... G12C is the most commonly detected KRAS mutation in NSCLC.
Edit

BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia (Bridgebio Oncology Therapeutics Inc)

Public Technologies 25 Oct 2025
BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS.PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia.
Edit

Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in ...

Nasdaq Globe Newswire 24 Oct 2025
Quanta presented positive Phase 1 data for QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with advanced cancer, including CRC, PDAC ... .
Edit

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS ...

Nasdaq Globe Newswire 24 Oct 2025
– In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in models of pancreatic, colorectal, and lung cancer – ... .

Article Search

tools
×
×
×
×